TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17975481

Group type: EXPERIMENTAL
Intervention: Nonselective beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variceal band ligation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Organic nitrates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Band ligation
Number of subjects: 0
Study: 15728228

Group type: EXPERIMENTAL
Intervention: Docetaxel/gemcitabine (DG): gemcitabine 1,000 mg/m(2) [days 1 and 8] plus docetaxel 100 mg/m(2) [day 8]
Number of subjects: 413

Group type: COMPARATOR
Intervention: Vinorelbine/cisplatin (VC): vinorelbine 30 mg/m(2) [days 1 and 8] plus cisplatin 80 mg/m(2) [day 8]
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Docetaxel/gemcitabine (DG)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Vinorelbine/cisplatin (VC)
Number of subjects: 413
Study: 12473800

Group type: EXPERIMENTAL
Intervention: Simplified grading of Gram stained smears (grades I, II, III, 0, IV)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Grade III smear assessment
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Grade I smear assessment
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Grade II smear assessment
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Grades 0 and IV smear assessments
Number of subjects: 162
Study: 10402622

Group type: EXPERIMENTAL
Intervention: Client interviewers
Number of subjects: 120

Group type: COMPARATOR
Intervention: Staff members
Number of subjects: 120
Study: 8821071

Group type: EXPERIMENTAL
Intervention: Nootropic drugs
Number of subjects: 61

Group type: COMPARATOR
Intervention: No additional treatment (nootropics)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High L-dopa dosage
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Nootropic drugs (responders)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No additional treatment (non-responders)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No additional treatment (responders)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Nootropic drugs (non-responders)
Number of subjects: 61
Study: 2166455

Group type: EXPERIMENTAL
Intervention: Low dose of inhaled terbutaline (LDT), 500 micrograms four times a day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High dose of inhaled terbutaline (HDT), 2,000 micrograms four times a day
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (ipratropium bromide during run-in and washout periods)
Number of subjects: 11
Study: 7219673

Group type: COMPARATOR
Intervention: Dopamine (DA) infusion (5 microgram/kg/min for 120 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: L-dopa (500 mg p.o.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: L-dopa (100 mg p.o.) plus carbidopa (35 mg p.o.) after pretreatment with carbidopa (50 mg p.o. every 6 h for 1 day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nomifensine (200 mg p.o.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control placebo study
Number of subjects: 0
Study: 31122969

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 663

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 663
Study: 29429912

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously every 4 weeks
Number of subjects: 1718

Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg intravenously every 4 weeks
Number of subjects: 1718

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 1718

Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 1718
Study: 26939082

Group type: EXPERIMENTAL
Intervention: Postnatal supplementation with docosahexaenoic acid (DHA) and arachidonic acid (AA)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 129
Study: 23458430

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (10 °C; CWI)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Mixed-method cooling (MIX)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 9
Study: 22828610

Group type: EXPERIMENTAL
Intervention: Personalised triage
Number of subjects: 3133

Group type: EXPERIMENTAL
Intervention: Computerised triage
Number of subjects: 3133

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 3133
Study: 19093122

Group type: EXPERIMENTAL
Intervention: 1.5 T
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3 T
Number of subjects: 20
Study: 17599307

Group type: EXPERIMENTAL
Intervention: G-CSF (granulocyte colony-stimulating factor), 263 mu g per day administered intravenously
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: G-CSF (granulocyte colony-stimulating factor)
Number of subjects: 60
Study: 14695004

Group type: EXPERIMENTAL
Intervention: Depleted uranium exposed soldiers with embedded shrapnel
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Depleted uranium exposed soldiers with no shrapnel
Number of subjects: 45

Group type: COMPARATOR
Intervention: Reference group of deployed soldiers not involved in friendly fire incidents
Number of subjects: 45
Study: 11845645

Group type: EXPERIMENTAL
Intervention: Factorial analysis of variance (ANOVA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariate analyses of variance (MANOVAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simple main effects analysis
Number of subjects: 0
Study: 11150968

Group type: EXPERIMENTAL
Intervention: Na(+)‐K(+)‐ATPase concentration in CHF males (n=27)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Na(+)‐K(+)‐ATPase concentration in CHF females (n=7)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Na(+)‐K(+)‐ATPase concentration in untrained CHF males (n=7)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Peak aerobic power (VO(2) peak) and Na(+)‐K(+)‐ATPase correlation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Peak aerobic power (VO(2) peak) and maximal citrate synthase activity correlation
Number of subjects: 34
Study: 9508663

Group type: EXPERIMENTAL
Intervention: Normal sodium diet (3 days)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Sodium restriction (30‐40 mmol Na/24 h for 3 days)
Number of subjects: 56
Study: 8197850

Group type: EXPERIMENTAL
Intervention: Biodegradable polyglycolic acid (PGA) rods (n=15)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Screws (n=17)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nondegradable osteosynthesis technique (reference group)
Number of subjects: 32
Study: 3051432

Group type: EXPERIMENTAL
Intervention: Computer-assisted learning program
Number of subjects: 83

Group type: COMPARATOR
Intervention: Weekly seminars with a cardiologist
Number of subjects: 83
Study: 1294383

Group type: EXPERIMENTAL
Intervention: Previous perinatal death
Number of subjects: 1324

Group type: EXPERIMENTAL
Intervention: Maternal diabetes
Number of subjects: 1324

Group type: EXPERIMENTAL
Intervention: Epilepsy
Number of subjects: 1324

Group type: EXPERIMENTAL
Intervention: Hydramnios
Number of subjects: 1324

Group type: EXPERIMENTAL
Intervention: Disproportion between fetus and pelvis
Number of subjects: 1324

Group type: EXPERIMENTAL
Intervention: Previous spontaneous abortion
Number of subjects: 1324

Group type: COMPARATOR
Intervention: Involuntary childlessness
Number of subjects: 1324

Group type: COMPARATOR
Intervention: Contraceptive use
Number of subjects: 1324

Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 1324
Study: 596499

Group type: EXPERIMENTAL
Intervention: Physicians
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physicians (IUD users)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurses (IUD users)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physicians (pill users)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurses (pill users)
Number of subjects: 0
Study: 30461089

Group type: EXPERIMENTAL
Intervention: Both parents being asthmatic
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Only the mother being asthmatic
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Uncontrolled maternal asthma during pregnancy
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Sufficient maternal vitamin D status (25Hydroxyvitamin D ≥ 30 ng/mL) during early and late pregnancy
Number of subjects: 806
Study: 29143400

Group type: EXPERIMENTAL
Intervention: 1 mg intranasal naloxone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 2 mg intranasal naloxone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 4 mg intranasal naloxone
Number of subjects: 38

Group type: COMPARATOR
Intervention: 0.4 mg intramuscular naloxone (reference)
Number of subjects: 38

Group type: COMPARATOR
Intervention: 0.4 mg intravenous naloxone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intranasal naloxone (1 mg, 2 mg, 4 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intramuscular naloxone (0.4 mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intranasal naloxone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Simulation of repeat dosing (2 x 2 mg i.n. vs 5 x 0.4 mg i.m.)
Number of subjects: 38
Study: 25857374

Group type: EXPERIMENTAL
Intervention: Self-efficacy education intervention (DVD demonstrating self-efficacy activities, undertaken four times before admission)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 91
Study: 25165090

Group type: EXPERIMENTAL
Intervention: Full Education combining a health belief module with a social‐cognitive theory module that provided hands‐on practice installing alarm batteries and using the alarm's hush button
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Hands‐on Practice social‐cognitive module supplemented by typical fire department education
Number of subjects: 436

Group type: COMPARATOR
Intervention: Current Norm receiving typical fire department education only
Number of subjects: 436
Study: 23101743

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication plus parent training (COMB)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Antipsychotic medication alone (MED)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: COMB group
Number of subjects: 124

Group type: COMPARATOR
Intervention: MED group
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: COMB families
Number of subjects: 124

Group type: COMPARATOR
Intervention: MED families
Number of subjects: 124
Study: 19640231

Group type: EXPERIMENTAL
Intervention: Ice packs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Analgesia injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hot water immersion
Number of subjects: 60
Study: 17200169

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR; 25% reduction in energy intake, n = 12)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Caloric restriction plus exercise (CR+EX; 12.5% reduction in energy intake + 12.5% increase in exercise energy expenditure, n = 12)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (healthy weight maintenance diet, n = 11)
Number of subjects: 35
Study: 16048603

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Cyclosporin (CyA)
Number of subjects: 196
Study: 11884252

Group type: EXPERIMENTAL
Intervention: SonoVue (0.5, 1, 2, and 4 ml)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SonoVue (cumulative 7.5 ml dose)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SonoVue (2.0 ml dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Albunex (two injections)
Number of subjects: 100
Study: 10211753

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 17
Study: 7788518

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg four times daily)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sustained release theophylline (maximum daily dose 13 mg/kg)
Number of subjects: 105
Study: 2086794

Group type: EXPERIMENTAL
Intervention: Subcuticular technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Interrupted transdermal technique
Number of subjects: 100
Study: 113095

Group type: EXPERIMENTAL
Intervention: Hexamethylmelamine (HEX) alone
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Hexamethylmelamine (HEX) combined with prophylactic pyridoxine
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (HEX alone)
Number of subjects: 98
Study: 30964423

Group type: EXPERIMENTAL
Intervention: sICM (7.2 g iodine) at 100 kVp
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: rICM (5.4 g iodine) at 100 kVp
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: sICM at 50 keV
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: rICM at 50 keV
Number of subjects: 200

Group type: COMPARATOR
Intervention: ICM (sICM and rICM)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: sICM and rICM
Number of subjects: 200

Group type: COMPARATOR
Intervention: BCM
Number of subjects: 200
Study: 29268759

Group type: EXPERIMENTAL
Intervention: 0.5% CHG
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: 1.0% CHG
Number of subjects: 796

Group type: COMPARATOR
Intervention: 10% PVI
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: 0.5% CHG vs. PVI
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: 1.0% CHG vs. PVI
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis (0.5% CHG vs. PVI)
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis (1.0% CHG vs. PVI)
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: CRBSI incidence
Number of subjects: 796
Study: 25522928

Group type: EXPERIMENTAL
Intervention: Water-based exercise
Number of subjects: 66

Group type: COMPARATOR
Intervention: Land-based exercise
Number of subjects: 66
Study: 24039176

Group type: EXPERIMENTAL
Intervention: Septal stapler
Number of subjects: 16

Group type: COMPARATOR
Intervention: Suture closure
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 16
Study: 21234545

Group type: EXPERIMENTAL
Intervention: Bioabsorbable screws
Number of subjects: 41

Group type: COMPARATOR
Intervention: Metal interference screws
Number of subjects: 41
Study: 19858762

Group type: EXPERIMENTAL
Intervention: MDD treatment (specific treatments not detailed, included pharmacological and cognitive-behavioral therapy)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Baseline substance-related impairment
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: High substance-related impairment (≥ 75th percentile)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Parental depressive symptoms
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: 12 week substance-related impairment scores
Number of subjects: 334

Group type: COMPARATOR
Intervention: Specific treatments (pharmacological or cognitive-behavioral therapy)
Number of subjects: 334
Study: 17354027

Group type: EXPERIMENTAL
Intervention: Intravenous phospholipid (PL) infusion (200 mg/kg) weekly for 8 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intravenous placebo infusion
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Operated carotid (after endarterectomy)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Unoperated carotid
Number of subjects: 39
Study: 15466720

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 438

Group type: COMPARATOR
Intervention: Brace treatment
Number of subjects: 438

Group type: COMPARATOR
Intervention: Range-of-motion exercises
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Femoral osteotomy
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Innominate osteotomy
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Surgical treatment (for lateral pillar B and B/C border groups)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Nonoperative treatment (for lateral pillar B and B/C border groups)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Nonoperative treatment (for lateral pillar group C)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Operative treatment (for lateral pillar group C)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Age at onset > 8.0 years
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Age at onset <= 8.0 years
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Female patients over 8.0 years
Number of subjects: 438
Study: 12102158

Group type: EXPERIMENTAL
Intervention: Longer delays in diagnosis and treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Shorter waiting times in diagnosis and treatment
Number of subjects: 0
Study: 10682561

Group type: EXPERIMENTAL
Intervention: 2 mg nylestriol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7619643

Group type: EXPERIMENTAL
Intervention: Lecture by a person with AIDS (PWA) revealing HIV positive status through heterosexual transmission
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Lecture by a person with AIDS (PWA) revealing HIV positive status through homosexual transmission
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Lecture by a person with AIDS (PWA) revealing HIV positive status through needle-sharing
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Lecture by a person with AIDS (PWA) revealing HIV positive status through blood transfusion
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control condition (neutral presenter with no HIV status disclosure)
Number of subjects: 260

Group type: COMPARATOR
Intervention: No contact (control condition)
Number of subjects: 260
Study: 2526866

Group type: EXPERIMENTAL
Intervention: Sodium intake of 1 mmol.kg‐1.day‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium intake of 3 mmol.kg‐1.day‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (1 and 3 mmol.kg‐1.day‐1)
Number of subjects: 20
Study: 1082365

Group type: EXPERIMENTAL
Intervention: Schedule 1: single intravenous push of cytosine arabinoside followed by oral methotrexate and intravenous vincristine, cycle repeated every 7 days.
Number of subjects: 98

Group type: COMPARATOR
Intervention: Schedule 2: three daily injections of cytosine arabinoside followed by vincristine and methotrexate, cycle repeated every 10 days.
Number of subjects: 98
Study: 30551218

Group type: EXPERIMENTAL
Intervention: Antidepressant users
Number of subjects: 42890

Group type: EXPERIMENTAL
Intervention: No use of antidepressants before IBD onset
Number of subjects: 42890

Group type: COMPARATOR
Intervention: Nonusers of antidepressants
Number of subjects: 42890
Study: 30060719

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (8 mL injected)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Oral pain medication alone (Control)
Number of subjects: 39
Study: 27389019

Group type: EXPERIMENTAL
Intervention: Essential Amino Acids and Keto-Analogues (EAA/KA) supplementation with low protein diet (LPD)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no EAA/KA supplementation)
Number of subjects: 96
Study: 24730361

Group type: EXPERIMENTAL
Intervention: 0.5 mL/kg of 24% sucrose with a pacifier
Number of subjects: 64

Group type: COMPARATOR
Intervention: 0.5 mL/kg of sterile water with a pacifier
Number of subjects: 64
Study: 22929989

Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (EOM)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo mouthrinse (P)
Number of subjects: 34
Study: 20585813

Group type: EXPERIMENTAL
Intervention: Intravenous DEX 0.3 μg kg⁻¹
Number of subjects: 81

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 81
Study: 17507354

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease present
Number of subjects: 146

Group type: COMPARATOR
Intervention: Chronic kidney disease absent
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Death or appropriate ICD therapy
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Cardiac death
Number of subjects: 146
Study: 15731473

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 400

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 400
Study: 12484432

Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9809861

Group type: EXPERIMENTAL
Intervention: Hydroxyzine (12.5 mg morning and mid-day, 25 mg evening)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo (three capsules/day)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Buspirone (5 mg morning and mid-day, 10 mg evening)
Number of subjects: 244
Study: 7666097

Group type: EXPERIMENTAL
Intervention: ChlVPP/EVA hybrid regimen
Number of subjects: 423
Study: 2711309

Group type: EXPERIMENTAL
Intervention: Phenytoin (15 mg/kg) administered intravenously shortly before surgery completion and 5‐6 mg/kg/day in three divided doses for the first 3 postoperative days.
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo administered under identical conditions to the control group of 185 patients.
Number of subjects: 189
Study: 598405

Group type: EXPERIMENTAL
Intervention: muzolimine 30 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: furosemide 40 mg
Number of subjects: 12
Study: 31377052

Group type: EXPERIMENTAL
Intervention: Alirocumab 75/150 mg Q2W
Number of subjects: 4983

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W
Number of subjects: 4983

Group type: COMPARATOR
Intervention: Control (ezetimibe + statin)
Number of subjects: 4983

Group type: COMPARATOR
Intervention: Control (placebo + statin)
Number of subjects: 4983

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4983
Study: 28732209

Group type: EXPERIMENTAL
Intervention: Peer education program on combating violence against women
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (no peer education)
Number of subjects: 136
Study: 26310577

Group type: EXPERIMENTAL
Intervention: Tackling Teenage Training (TTT) program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 200
Study: 23248207

Group type: EXPERIMENTAL
Intervention: Intercostal nerve cryoanalgesia (INC)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Non-divided intercostal muscle flap (NIMF)
Number of subjects: 160
Study: 21270655

Group type: EXPERIMENTAL
Intervention: 2 minutes of exercise five days a week
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 12 minutes of exercise five days a week
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Longer exercise program (12 minutes)
Number of subjects: 132
Study: 18443989

Group type: EXPERIMENTAL
Intervention: Spiritually based educational booklet
Number of subjects: 108

Group type: COMPARATOR
Intervention: Secular educational booklet
Number of subjects: 108